Hemab Therapeutics, a biotechnology company in the clinical stage that focuses on creating new preventative treatments for rare and overlooked bleeding and blood clotting disorders, has announced that they successfully raised $157 million through their Series C funding round, which was more than enough money requested. This round was led by Sofinnova Partners, with strong backing from a big global investment company, a major sovereign wealth fund, and Avoro Capital Advisors. Existing investors such as RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Avoro Ventures, Maj Invest Equity, and Rock Springs Capital also continued to support the company. Joe Anderson, PhD, a partner at Sofinnova Partners, will now be joining Hemab’s board of directors due to this financing.
Health Technology Insights: Dermatology of Miami Adds Dr. George Glinos to Team
This money will help speed up the development of sutacimig, Hemab’s first preventative treatment for Glanzmann thrombasthenia, a rare blood disorder that can cause life-threatening bleeding. After promising results from a Phase 2 trial, Hemab intends to move sutacimig into a registration study in 2026 and start a Phase 2 trial for Factor VII deficiency. Alexandra Sullivan, who is a patient advocate and the mother of two boys with GT, shared the urgent need for better treatments, describing her constant worry about serious bleeding episodes and hoping that new therapies can allow children to live more normal lives.
The funding also helps support Hemab’s HMB-002 program, an antibody-based treatment for Von Willebrand disease that has shown in Phase 1 studies the ability to directly target the root cause of the disorder by increasing both Von Willebrand Factor and Factor VIII levels. Jeanette Cesta, Executive Director of the VWD Connect Foundation, pointed out the importance of HMB-002, stating that patients with VWD have been waiting for innovative preventative therapies similar to those available for hemophilia and that she is hopeful that this treatment could bring meaningful improvements to their lives.
Health Technology Insights: Cohere Health Launches AI Prior Authorization Tool
Patient input has been a key part of Hemab’s research, shaping programs such as GT360, FVIID360, and VWD360. These studies have shown the heavy burdens patients face beyond acute bleeding, including chronic pain, limited movement, anxiety, depression, and fatigue. Hemab uses these insights to guide the creation of therapies that tackle both immediate and long-term needs. The company plans to keep expanding its treatment options, with HMB-003 expected to start clinical development in the first half of 2026, reinforcing Hemab’s mission to provide a wide range of treatments for people dealing with serious bleeding disorders.
Benny Sorensen, MD, PhD, and CEO of Hemab, said that this financing and the caliber of the investors confirm the company’s patient-centered approach and its strategy to build what he calls the ultimate clotting company. He stressed Hemab’s commitment to working closely with patients and their families to deliver next-generation treatments and highlighted the team’s expertise in taking treatments from early development all the way to commercialization. Joe Anderson, PhD, Partner at Sofinnova Partners, added that Hemab’s combination of scientific excellence, innovative strategy, and clinical progress across several programs makes it a standout company in the biotech industry and that they are excited to support the mission of bringing transformative therapies to underserved patient groups.
Health Technology Insights: LGC Group Opens New UK Labs to Boost Measurement Science
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
